These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 18671910

  • 1. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L.
    Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
    [Abstract] [Full Text] [Related]

  • 2. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 4. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.
    Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V.
    Neurol Sci; 2003 Oct 15; 24(3):199-200. PubMed ID: 14598086
    [Abstract] [Full Text] [Related]

  • 5. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb 15; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 6. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Feb 15; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 7. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.
    Arch Neurol; 2003 Dec 15; 60(12):1696-702. PubMed ID: 14676043
    [Abstract] [Full Text] [Related]

  • 8. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul 15; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 9. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb 15; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 10. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.
    Neurobiol Aging; 2006 Sep 15; 27(9):1202-11. PubMed ID: 16085339
    [Abstract] [Full Text] [Related]

  • 11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.
    J Med Assoc Thai; 2011 Feb 15; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [Abstract] [Full Text] [Related]

  • 12. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 13. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.
    Dement Geriatr Cogn Disord; 2007 Dec 21; 23(5):316-20. PubMed ID: 17374949
    [Abstract] [Full Text] [Related]

  • 14. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Rüther E, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2007 Jul 21; 12(7):671-80. PubMed ID: 17339876
    [Abstract] [Full Text] [Related]

  • 15. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.
    Neurobiol Aging; 2009 Feb 21; 30(2):165-73. PubMed ID: 17646035
    [Abstract] [Full Text] [Related]

  • 16. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
    Herukka SK, Hallikainen M, Soininen H, Pirttilä T.
    Neurology; 2005 Apr 12; 64(7):1294-7. PubMed ID: 15824371
    [Abstract] [Full Text] [Related]

  • 17. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.
    J Intern Med; 2004 Sep 12; 256(3):205-23. PubMed ID: 15324364
    [Abstract] [Full Text] [Related]

  • 18. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
    Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Mariën P, De Deyn PP.
    Neurochem Int; 2006 Mar 12; 48(4):286-95. PubMed ID: 16434124
    [Abstract] [Full Text] [Related]

  • 19. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A.
    J Int Neuropsychol Soc; 2008 Jul 12; 14(4):582-90. PubMed ID: 18577287
    [Abstract] [Full Text] [Related]

  • 20. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls.
    Pijnenburg YA, Janssen JC, Schoonenboom NS, Petzold A, Mulder C, Stigbrand T, Norgren N, Heijst H, Hack CE, Scheltens P, Teunissen CE.
    Dement Geriatr Cogn Disord; 2007 Jul 12; 23(4):225-30. PubMed ID: 17290105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.